Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Prophase Labs ( (PRPH) ) has issued an update.
On January 26, 2026, ProPhase Labs, Inc. announced it had issued an operational update on the progress of its Crown Medical Collections initiative, which concerns legacy COVID-19 testing receivables tied to its laboratory subsidiaries that are currently in Chapter 11 proceedings. The update underscores the company’s ongoing efforts to address and manage outstanding pandemic-era testing receivables in the context of its subsidiaries’ bankruptcy process, an issue of material importance to its security holders given the potential impact on recoveries and financial positioning.
The most recent analyst rating on (PRPH) stock is a Sell with a $0.24 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
Spark’s Take on PRPH Stock
According to Spark, TipRanks’ AI Analyst, PRPH is a Neutral.
The score is held down primarily by weak financial performance (sharp revenue decline, ongoing losses, and negative operating/free cash flow) and a bearish technical trend. Offsetting this somewhat is a mixed but potentially catalyst-driven earnings-call backdrop (claims collections and asset/partner optionality), while valuation is difficult to support with a negative P/E and no dividend.
To see Spark’s full report on PRPH stock, click here.
More about Prophase Labs
Average Trading Volume: 1,174,898
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.25M
See more data about PRPH stock on TipRanks’ Stock Analysis page.